Life Sciences Tools and Services
Company Overview of RainDance Technologies, Inc.
RainDance Technologies, Inc. develops genomic tools for non-invasive liquid biopsy applications for the research, early detection, and treatment of cancer, and other inherited and infectious diseases. It offers RainDrop, a digital polymerase chain reaction platform that generates picoliter-sized droplets for multiplex detection of HIV, DNA, or RNA; and consumables, such as source chips and sense chips, and oil surfactants. The company provides ThunderStorm, an automated next-generation sequencing (NGS) content enrichment solution that enable researchers to process various samples per day and generate quality data; ThunderBolts, a NGS panel for profiling important cancer mutations; ThunderBol...
749 Middlesex Turnpike
Billerica, MA 01821
Founded in 2004
Key Executives for RainDance Technologies, Inc.
Chief Executive Officer, President and Director
Co-Founder and Chief Technology Officer
Compensation as of Fiscal Year 2015.
RainDance Technologies, Inc. Key Developments
RainDance Technologies, Inc. Appoints Kathy Ordonez as the Chairman of the Board of Directors
Sep 24 15
RainDance Technologies, Inc. announced the appointment of Kathy Ordoez as chairman of its board of directors. Ms. Ordoez brings more than 30 years of experience in the life sciences and diagnostics industries, and has served on the board of directors since 2014, and as the chair of the board’s science and innovation committee. As senior vice president at Quest Diagnostics, Kathy Ordoez was responsible for leading the company's businesses in diagnostic products, insurer services, clinical trials and healthcare information technology products and also led research and development. Ordoez was previously the chief executive officer at Celera and a founder of Celera Diagnostics.
Pacific Biosciences of California, Inc. and RainDance Technologies, Inc. Partner to Co-Develop and Commercialize Novel Solution For de novo Whole Genome Assembly
May 5 15
Pacific Biosciences of California, Inc. and RainDance Technologies, Inc. announced their entry into a co-development and co-marketing agreement to commercialize novel solutions for de novo whole genome assembly. These solutions will combine the power of RainDance's proprietary digital droplet technology and single-molecule barcoding capabilities with Pacific Biosciences' proprietary long-range DNA amplification technology to provide sample preparation upstream of PacBio's long-read sequencing system. This combination could provide a method to generate millions of long, single-molecule barcoded DNA fragments, averaging 10-30 kilobases that originated from much longer (100 kilobase) fragments. Combining this fragmentation and labeling scheme with a sequence context-unbiased amplification method for long DNA fragments, PacBio sequencing could provide de novo, haplotype-phased assembly of complex genomes. This would be possible even in genomic regions containing complex repeats or PCR-challenged sequences that limit performance of synthetic long-read approaches based upon short-read sequencing technologies. Furthermore, this approach will be designed to work with low DNA input as little as 1 ng to address scarce or difficult-to-procure samples.
RainDance Technologies, Inc. Announces Global Availability of the Thunderbolts Myeloid Panel
Apr 20 15
RainDance Technologies, Inc. announced global availability of the ThunderBolts Myeloid Panel, a next-generation sequencing (NGS) research assay designed to rapidly detect and cost-effectively analyze genetic mutations associated with AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndromes), MPN (Myeloproliferative Neoplasms) and other myeloid cancer research. The research assay was developed with the RainDanceHemOnc Consortium, a select group of hematologic oncology experts drawn from prominent academic and cancer research centers in the U.S. and Europe. HemOnc Consortium members will present the latest performance data from the new panel during the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia on April 18-22, 2015. The ThunderBolts Myeloid Panel is a pre-validated NGS assay for researching mutations and hotspots in 49 important genes implicated in the causation, prognosis and recurrence of certain blood and bone marrow cancers. The panel features NGS breakthroughs in low sample input (10 ng), high sequencing coverage (100 percent), uniformity (greater than 95 percent), and time-to-result (2.5 days). Scientists are using the ThunderBolts Myeloid Panel to profile mutations that can then be independently validated and monitored with the ultra-sensitive RainDrop® Digital PCR System, all based on a unified and single droplet technology platform. The HemOnc Consortium is continuing to work with RainDance to conduct research into a proprietary digital PCR portfolio of cell-free mutation assays to study and monitor the status of important genes in blood-based cancer progression and relapse.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|